{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:49Z","timestamp":1790983009989,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2024S001"],"award-info":[{"award-number":["2024S001"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01731-0","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:47:08Z","timestamp":1790084828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6610-7044","authenticated-orcid":false,"given":"Thibault","family":"Viguier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-1928","authenticated-orcid":false,"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8483-5023","authenticated-orcid":false,"given":"Alex","family":"Hlavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-8573","authenticated-orcid":false,"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-5483","authenticated-orcid":false,"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1731_CR1","unstructured":"Caisse nationale de l\u2019Assurance Maladie (CNAM). Open Medic: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments interr\u00e9gimes [Internet]. https:\/\/www.data.gouv.fr\/datasets\/open-medic-base-complete-sur-les-depenses-de-medicaments-interregimes. Accessed 24 Aug 2026."},{"issue":"3","key":"1731_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43(3):558\u201382. https:\/\/doi.org\/10.1210\/endrev\/bnab035.","journal-title":"Endocr Rev"},{"issue":"4","key":"1731_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154498","volume":"11","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous CA. Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PLoS\u00a0One. 2016;11(4):e0154498. https:\/\/doi.org\/10.1371\/journal.pone.0154498.","journal-title":"PLoS\u00a0One"},{"issue":"39","key":"1731_CR4","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","volume":"37","author":"HM Colhoun","year":"2016","unstructured":"Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, M\u00fcller-Wieland D, Henry RR, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. Eur Heart J. 2016;37(39):2981\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehw292.","journal-title":"Eur Heart J"},{"issue":"12","key":"1731_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1731_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030364","volume":"17","author":"F Calapai","year":"2024","unstructured":"Calapai F, Mannucci C, Curr\u00f2 M, Cardia L, Esposito E, Calapai G, et al. Adverse reactions to evolocumab: analysis of real-world data from EudraVigilance. Pharmaceuticals (Basel). 2024;17(3):364. https:\/\/doi.org\/10.3390\/ph17030364.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1731_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894685","volume":"13","author":"Z Feng","year":"2022","unstructured":"Feng Z, Li X, Tong WK, He Q, Zhu X, Xiang X, et al. Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS. Front Pharmacol. 2022;13:894685. https:\/\/doi.org\/10.3389\/fphar.2022.894685.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1731_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40801-024-00430-5","volume":"11","author":"D Park","year":"2024","unstructured":"Park D, Bea S, Bae JH, Lee H, Choe YJ, Shin JY, et al. PCSK9 inhibitors and infection-related adverse events: a pharmacovigilance study using the World Health Organization VigiBase. Drugs. 2024;11(3):465\u201375. https:\/\/doi.org\/10.1007\/s40801-024-00430-5.","journal-title":"Drugs"},{"issue":"9","key":"1731_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/eurjpc\/zwab209","volume":"29","author":"A Goldman","year":"2022","unstructured":"Goldman A, Raschi E, Cukierman-Yaffe T, Dankner R, Shouval R, Shechter M, et al. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. Eur J Prev Cardiol. 2022;29(9):1334\u201342. https:\/\/doi.org\/10.1093\/eurjpc\/zwab209.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1731_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10557-021-07242-7","volume":"37","author":"A Gouverneur","year":"2023","unstructured":"Gouverneur A, Sanchez-Pena P, Veyrac G, Salem JE, B\u00e9gaud B, Bezin J. Neurocognitive disorders associated with PCSK9 inhibitors: a pharmacovigilance disproportionality analysis. Cardiovasc Drugs Ther. 2023;37(2):271\u20136. https:\/\/doi.org\/10.1007\/s10557-021-07242-7.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"1731_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14522","volume":"30","author":"Z Deng","year":"2023","unstructured":"Deng Z, Liu J, Gong H, Cai X, Xiao H, Gao W. Psychiatric disorders associated with PCSK9 inhibitors: a real\u2010world, pharmacovigilance study. CNS Neurosci Ther. 2023;30(4):e14522. https:\/\/doi.org\/10.1111\/cns.14522.","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"1731_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"issue":"6","key":"1731_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399. https:\/\/doi.org\/10.1007\/s40264-024-01423-7.","journal-title":"Drug Saf"},{"issue":"4","key":"1731_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"1731_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362. https:\/\/doi.org\/10.1002\/pds.4233.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1731_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-40791-1","volume":"16","author":"A Singier","year":"2026","unstructured":"Singier A, B\u00e9nard-Laribi\u00e8re A, Jarne-Munoz A, Pariente A, Veyrac G, Bezin J. PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies. Sci Rep. 2026;16(1):8866. https:\/\/doi.org\/10.1038\/s41598-026-40791-1.","journal-title":"Sci Rep"},{"issue":"1","key":"1731_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29(1):5\u2013115. https:\/\/doi.org\/10.1093\/eurjpc\/zwab154.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1731_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","volume":"22","author":"IA Wahab","year":"2013","unstructured":"Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22(5):496\u2013502. https:\/\/doi.org\/10.1002\/pds.3417.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1731_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","volume":"4","author":"M Hauben","year":"2005","unstructured":"Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929\u201348. https:\/\/doi.org\/10.1517\/14740338.4.5.929.","journal-title":"Expert Opin Drug Saf"},{"key":"1731_CR20","unstructured":"Metathesaurus. In: UMLS\u00ae reference manual [Internet] [Internet]. National Library of Medicine (US); 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK9684\/. Accessed 18 Jan 2026."},{"key":"1731_CR21","unstructured":"CIM-10 FR. Classification statistique internationale des maladies et des probl\u00e8mes de sant\u00e9 connexes \u00e0 usage PMSI. 10e r\u00e9vision, France. ATIH. [Internet]. https:\/\/www.atih.sante.fr\/sites\/default\/files\/public\/content\/4216\/cim-10-fr_2022_a_usage_pmsi.pdf. Accessed 24 Aug 2026."},{"key":"1731_CR22","unstructured":"ICD-10 to MedDRA Mapping Conventions. June 2024. World Health Organization. [Internet]. https:\/\/cdn.who.int\/media\/docs\/default-source\/classification\/icd\/icd-10\/icd-10-to-meddra-mapping-conventions---june-2024.pdf?sfvrsn=5b9ddad6_1. Accessed 24 Aug 2026."},{"issue":"7","key":"1731_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"ECC Lai","year":"2017","unstructured":"Lai ECC, Pratt N, Hsieh CY, Lin SJ, Potteg\u00e5rd A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567\u201382. https:\/\/doi.org\/10.1007\/s10654-017-0281-8.","journal-title":"Eur J Epidemiol"},{"issue":"68","key":"1731_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14689\/ejer.2017.68.1","volume":"17","author":"CD Do\u011fan","year":"2017","unstructured":"Do\u011fan CD. Applying bootstrap resampling to compute confidence intervals for various statistics with R. Eurasian J Educ Res. 2017;17(68):1\u201318. https:\/\/doi.org\/10.14689\/ejer.2017.68.1.","journal-title":"Eurasian J Educ Res"},{"issue":"3","key":"1731_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40264-015-0375-8","volume":"39","author":"M Arnaud","year":"2016","unstructured":"Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, B\u00e9gaud B, et al. A method for the minimization of competition bias in signal detection from spontaneous reporting databases. Drug Saf. 2016;39(3):251\u201360. https:\/\/doi.org\/10.1007\/s40264-015-0375-8.","journal-title":"Drug Saf"},{"issue":"10","key":"1731_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF03261981","volume":"35","author":"A Pariente","year":"2012","unstructured":"Association Fran\u00e7aise des Centres R\u00e9gionaux de Pharmacovigilance (CRPV), Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, et al. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf. 2012;35(10):855\u201364. https:\/\/doi.org\/10.1007\/BF03261981.","journal-title":"Drug Saf"},{"issue":"1","key":"1731_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J. Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep. 2023;13(1):18817. https:\/\/doi.org\/10.1038\/s41598-023-46275-w.","journal-title":"Sci Rep"},{"issue":"1","key":"1731_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1731_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case\u2013non-case studies: principle, methods, bias and interpretation. Therapies. 2019;74(2):225\u201332. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006.","journal-title":"Therapies"},{"issue":"1","key":"1731_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002196","volume":"12","author":"CP Nelson","year":"2019","unstructured":"Nelson CP, Lai FY, Nath M, Ye S, Webb TR, Schunkert H, et al. Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors. Circ Genom Precis Med. 2019;12(1):e002196. https:\/\/doi.org\/10.1161\/CIRCGEN.118.002196.","journal-title":"Circ Genom Precis Med"},{"key":"1731_CR31","unstructured":"Lorant V. Effets de PCSK9 sur l\u2019allergie [Theses] [Internet]. Nantes Universit\u00e9; 2023. https:\/\/theses.hal.science\/tel-04426253. Accessed 24 Aug 2026."},{"issue":"9","key":"1731_CR32","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/jcp.25767","volume":"232","author":"F Paciullo","year":"2017","unstructured":"Paciullo F, Fallarino F, Bianconi V, Mannarino MR, Sahebkar A, Pirro M. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J Cell Physiol. 2017;232(9):2330\u20138. https:\/\/doi.org\/10.1002\/jcp.25767.","journal-title":"J Cell Physiol"},{"key":"1731_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.sleep.2024.09.045","volume":"124","author":"C Jambon-Barbara","year":"2024","unstructured":"Jambon-Barbara C, Revol B, Hlavaty A, Joyeux-Faure M, Borel JC, Cracowski JL, et al. Signal detection of drugs associated with obstructive and central sleep apnoea. Sleep Med. 2024;124:315\u201322. https:\/\/doi.org\/10.1016\/j.sleep.2024.09.045.","journal-title":"Sleep Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01731-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01731-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01731-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:47:13Z","timestamp":1790084833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01731-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":33,"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01731-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare (including financial interests, professional interests, personal relationships, and personal beliefs) that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics committee approval was required for this observational study based on French medico-administrative databases because of the anonymous nature of the data, by agreement of the French Data Protection Supervisory Authority (CNIL).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No informed consent to participate was required for this observational study based on French medico-administrative databases because of the anonymous nature of the data, by agreement of the French Data Protection Supervisory Authority (CNIL).","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No consent for publication was required for this observational study based on French medico-administrative databases because of the anonymous nature of the data.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the French Data Protection Authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, CNIL) via the French Health Data Hub (French law to access SNDS\n                      \n                      ). Restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.","order":5,"name":"Ethics","label":"Availability of Data and Material:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Codes of outcomes are provided in the Electronic Supplementary Material. The statistical code is not publicly available but may be provided upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TV: design, data analysis and results interpretation, and drafting of the manuscript; JB: design, results interpretation, and critical revision of the manuscript; AH: design, data analysis and results interpretation, and critical revision of the manuscript; CK: design, results interpretation, and critical revision of the manuscript; AP: coordination, design, results interpretation, and critical revision of the manuscript.\u00a0All authors read and approved the final version.\u00a0","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Large language models (LLM) models have been used on an ad hoc basis to refine or polish the style.","order":8,"name":"Ethics","label":"Artificial Intelligence (AI) Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}